AERIE PHARMACEUTICALS, INC. Up to $75,000,000 of Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales AgreementAerie Pharmaceuticals Inc • December 19th, 2017 • Biological products, (no disgnostic substances) • New York
Aerie Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (“CF&Co”) (the “Agent”), as follows:
